Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22.
Neurofibromatosis 2 or bilateral acoustic neurofibromatosis (NF2) is a severe autosomal dominant disorder characterized by the development of multiple tumors of the nervous system, including meningiomas, gliomas, neurofibromas, ependymomas, and particularly acoustic neuromas. Polymorphic DNA markers have revealed frequent loss of one copy of chromosome 22 in the tumor types associated with NF2. Family studies have demonstrated that the primary defect in NF2 is linked to DNA markers on chromosome 22, suggesting that it involves inactivation of a tumor suppressor gene. We have employed a combination of multipoint linkage analysis and examination of deletions in primary tumor specimens to precisely map the NF2 locus between flanking polymorphic DNA markers on chromosome 22. The 13-cM region bracketed by these markers corresponds to 13% of the genetic length of the long arm of chromosome 22 and is expected to contain less than 5 x 10(6) bp of DNA. The delineation of flanking markers for NF2 should permit accurate presymptomatic and prenatal diagnosis for the disorder and greatly facilitate efforts to isolate the defective gene on the basis of its location.
Rouleau
G A
GA
Neurogenetics Laboratory, Massachusetts General Hospital, Charlestown 02129.
Seizinger
B R
BR
Wertelecki
W
W
Haines
J L
JL
Superneau
D W
DW
Martuza
R L
RL
Gusella
J F
JF
D000483:Alleles; D002874:Chromosome Mapping; D002892:Chromosomes, Human, Pair 22; D015342:DNA Probes; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D008040:Genetic Linkage; D005819:Genetic Markers / Q000032:analysis; D006801:Humans; D008126:Lod Score; D008214:Lymphocytes / Q000473:pathology; D009456:Neurofibromatosis 1 / Q000235:genetics*; D009464:Neuroma, Acoustic / Q000235:genetics; D015183:Restriction Mapping
D015342:DNA Probes; D004273:DNA, Neoplasm; D005819:Genetic Markers